On the sensitivity of PROMs during breast radiotherapy.
Breast cancer
Irradiation
Partial breast
Patient reported outcome measures
Quality of life
eHealth
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
15
12
2022
accepted:
19
12
2022
entrez:
12
1
2023
pubmed:
13
1
2023
medline:
13
1
2023
Statut:
epublish
Résumé
To investigate the sensitivity of patient-reported outcome measures (PROMs) to detect treatment-related side effects in patients with breast cancer undergoing external beam photon radiotherapy. As part of daily clinical care, an in-house developed PROM tool was used to assess side effects in patients during a) whole-breast irradiation (WBI) to 40 Gy, b) WBI with a sequential boost of 10 Gy, and c) partial-breast irradiation (PBI) to 40 Gy. 414 patients participated in this prospective study between October 2020 and January 2022, with 128 patients (31 %) receiving WBI, 241 (58 %) receiving WBI followed by a sequential boost, and 50 patients (12 %) receiving PBI. Significant differences in the reported toxicities (itching, radiation skin reaction, skin darkening, and tenderness and swelling) were reported between the WBI cohorts with and without boost (p < 0.001, p < 0.001, p < 0.001, and p = 0.002, respectively). The comparison of PBI with WBI (no-boost) yielded significant differences for radiation skin reaction (p < 0.001). The results highlight the high sensitivity of PROMs to detect treatment-related side effects in patients with breast cancer. Thus, PROMs may be a valuable tool for quality control and may support evidence-based learning from real-world data originating from daily routine care.
Identifiants
pubmed: 36632055
doi: 10.1016/j.ctro.2022.100572
pii: S2405-6308(22)00130-6
pmc: PMC9827355
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100572Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
World J Urol. 2021 Oct;39(10):3979-3991
pubmed: 33963916
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Lancet Oncol. 2022 Jan;23(1):e21-e31
pubmed: 34973228
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
Strahlenther Onkol. 2020 Sep;196(9):749-763
pubmed: 32350554
Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):44-52
pubmed: 30102201
Radiother Oncol. 2021 Nov;164:183-195
pubmed: 34619237
Lancet Oncol. 2015 Jan;16(1):47-56
pubmed: 25500422
Ann Surg Oncol. 2018 Nov;25(12):3563-3571
pubmed: 30178391
Lancet. 2020 May 23;395(10237):1613-1626
pubmed: 32580883
J Natl Cancer Inst. 2014 Sep 29;106(9):
pubmed: 25265940
J Med Radiat Sci. 2021 Jun;68(2):186-195
pubmed: 32815314
Front Oncol. 2021 Mar 23;11:649301
pubmed: 33833998